I. COMMENCED TRADING IN JANUARY

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%


INITIAL OFFERINGS

There were no initial public offerings that commenced in January.

Total: $0M

Number of IPOs in January: 0

Average value of January IPOs: $0M

Number of IPOs in 2007: 0

Total raised in IPOs in 2007: $0M

Average value of IPOs in 2007: $0M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-Offering
Market
Cap (M)%


Allos
Therapeutics Inc.
(ALTH)1

1/30

1/30

9S

$6

65.7

Merrill Lynch & Co., Banc of America (Co-lead), JMP Securities LLC

$54

$394.2

Aradigm Corp.
(ARDM)2

10/24/06

1/25

38S

$0.95

49.5

Punk, Ziegel & Co., Merriman Curhan Ford & Co.

$36.1

$47

Cardiome
Pharma Corp.
(CRME)3

1/18

1/18

9.2S

$10.50

62.8

Bear, Stearns & Co., CIBC World Markets (co-lead), Canaccord Adams Leerink Swann & Co.

$96.6

$659.4

MediciNova Inc.
(MNOV)4

1/29

1/29

1S

$12

11.3

MDB Capital Group LLC

$12

$135.6

Nastech
Pharmaceutical
Co. Inc.
(NSTK)5

1/18

1/18

3.25S

$13.20

25.25

UBS Investment Bank

$42.9

$333.3

NicOx SA
(France;
Eurolist:NICOX)6

1/24**

1/24**

N/A

N/A

N/A

Merrill Lynch Internat, UBS Investment Bank, Lazard Natixis, Piper Jaffray

€130 (US$168.4)

N/A

Repros Therapeutics Inc. (RPRX)7

1/31/07

1/31/07

2.6S

$13.75

12.8

CIBC World Markets, Punk, Ziegel & Co. (Co-lead), ThinkEquity Partners LLC

$35.9

$176

Vanda
Pharmaceuticals
Inc.
(VNDA)8

1/19

1/19

4.4S

$27.29

26.53

JPMorgan Securities, Morgan Stanely (co- lead), Banc of America Securities, Natexis Bleichroeder Inc.

$120.1

$724

OVERALLOTMENT OPTIONS

Omrix Bio-
pharmaceuticals
Inc.
(OMRI)9

12/4/06

1/12/07

0.24S

$32

16.6

UBS Investment Bank, Citigroup (co-lead), CIBC World Markets, Rodman & Renshaw

$7.5

$531.2

Total: $573.5M

Number of follow-on offerings in January: 8

Average value of January follow-ons: $71.69M

Number of follow-on offerings in 2007: 8

Total raised in follow-ons in 2007: $573.5M

Average value of follow-ons in 2007: $71.69M


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

** Denotes the date the item ran in BioWorld International.

Currency conversions are based on exchange rates at the time of the deal.

1. Allos' offering was expected to include a 3.3-million share purchase from Baker Brothers Life Sciences LP and affiliated Funds.

2. Aradigm's offering includes the exercise of an overallotment option.

3. Cardiome's offering includes the exercise of an underwriters option to purchase an additional 1.2M common shares.

4. MediciNova's sole underwriter has a 150,000-share overallotment option.

5. Nastech has granted the underwriter an option to purchase up to an additional 487,500 shares to cover over-allotments in the offering, if any.

6. NicOx is raising $168.4M through the sale of stock that is open to the public in France only and is a transaction that gives existing shareholders preferential rights.

7. Repros' underwriters have an overallotment option for 390,000 shares.

8. Vanda's offering includes the underwriters' option to purchase up to 570,000 additional shares to cover overallotments.

9. Omrix raised an additional $7.5M through the exercise of the full overallotment option to purchase 235,109 shares. This brings the total number of shares offered to 1.7 million and the gross proceeds to about $55.5 million.

II. FILED AND PENDING

Company
(Symbol/
Proposed
Symbol)#*

Date Filed

Shares/
Units (M)

Price Range

Shares Out (M)@

Lead, Other Underwriters

Value (M)


INITIAL OFFERINGS

3SBIO Inc. (SSRX)1

1/22/07

7.2S

$12-$14

N/A

UBS Investment Bank, CIBC World Markets, Pacific Growth Equities

$93.6

Cellectis SA
(France; Euronext)2

12/26/06

2.38S

€8.90 to €10.25

N/A

N/A

$25

Light Sciences
Oncology Inc.
(LSON)3

4/21/06

5.25S

$14-$16

N/A

Cowen & Co., Wachovia Securities (co-lead), Jefferies & Co. Thomas Weisel Partners

$78.75

Molecular
Insight
Pharmaceuticals
Inc.
(MIPI)4

11/8/05

N/A

N/A

N/A

Piper Jaffray & Co., Cowen & Co. (co-lead), Oppenheimer & Co., Roth Capital Partners

$57.5

OncoGenex
Technologies
Inc.
(Canada;
OGXI; TSX:OGX)5

12/13/06

N/A

N/A

N/A

RBC Capital Markets, Needham & Co., Lazard Capital Markets, Canaccord Adams, Susquehanna Financial Group

$48

Optimer
Pharmaceuticals
Inc.
(OPTR)6

11/9/06

N/A

N/A

N/A

Piper Jaffray & Co., Jefferies & Co. (co-lead), JMP Securities, Rodman & Renshaw

$86.25

Orexigen
Therapeutics
Inc.
(OREX)7

12/16/06

N/A

N/A

N/A

Merrill Lynch & Co., JP Morgan Securities (co-lead), JMP Securities, Leerink Swann & Co.

$86.25

Perlegen
Sciences Inc.
(PERL)8

4/10/06

N/A

N/A

N/A

Lehman Brothers, Deutsche Bank Securities (co-lead), Piper Jaffray & Co., Allen & Co.

$115

Pharmasset
Inc.
(VRUS)9

5/9/06

N/A

N/A

N/A

Banc of America Securities, UBS Investment Bank (co-lead), JMP Securities

$75

PTC
Therapeutics
Inc.
(PTCT)10

3/31/06

N/A

N/A

N/A

Morgan Stanley & Co., JP Morgan Securities (co-lead), Pacific Growth Equities

$86.25

Rosetta
Genomics Ltd.
(Israel; ROSG)11

9/7/06

3S

$11-$13

N.A

C.E. Unterberg, Towbin, Oppenheimer & Co., Maxim Group

$36

Sucampo
Pharmaceuticals
Inc.
(SCMP)12

6/19/06

N/A

N/A

N/A

Banc of America Securities, Deutsche Bank Securities (co- ead), Leerink Swann & Co.

$86.25

Synta
Pharmaceuticals
Corp.
(SNTA)13

11/22/06

N/A

N/A

N/A

Bear, Stearns & Co., Lehman Brothers (co-lead), Lazard Capital Markets, Montgomery & Co.

$115

FOLLOW-ON OFFERINGS

Neurochem Inc.
(NRMX)14

1/18/07

NA

NA

N/A

N/A

$102

SemBioSys
Genetics Inc.
(Canada; TSX:SBS)15

1/16/07

N/A

N/A

N/A

Raymond James Ltd.

C$20
(US$17)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

TSX = Toronto Stock Exchange.

1. 3SBIO filed for its IPO of 7.2M American Depositary shares, representing 50.3M ordinary shares. If priced at $13, the midpoint of the price range, the company would raise $93.6M gross.

2. Cellectis launched its IPO on the Alternext market of the Paris Euronext stock exchange. It was expected to close Feb. 5.

3. Light Sciences Oncology filed to raise up to $86.25M in an IPO. The shares and price range were estimated in September. The value is based on the midpoint of those estimates.

4. Molecular Insight filed to raise up to $57.5M in an IPO.

5. OncoGenex filed to raise up to $48M in an IPO in both the U.S. and Canada.

6. Optimer filed to raise up to $86.25M in an IPO.

7. Orexigen filed to raise up to $86.25M in an IPO.

8. Perlegen filed to raise up to $115M in an IPO.

9. Pharmasset filed to raise up to $75M in an IPO.

10. PTC Therapeutics filed to raise up to $86.25M in an IPO.

11. Rosetta filed to raise $36M in an IPO on Nasdaq, based on the midpoint of the estimated price range.

12. Sucampo filed to raise up to $86.25M in an IPO.

13. Synta filed to raise up to $115M in an IPO. A previous IPO attempt was postponed in 2005.

14. Neurochem filed registration statements for $102M in Canada and the U.S. including the resale of up to $60M of its common shares and the re4sale of 6% senior convertible notes.

15. SemBioSys Genetics filed a preliminary prospectus in Canada to offer common stock; if gross porceeds exceed C$20M then certain existing shareholders would be able to sell shares in a secondary offering.